Trials / Conditions / Upper Tract Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

20 registered clinical trials studyying Upper Tract Urothelial Carcinoma — 12 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract NCT07498907	Peking University First Hospital	Phase 2
Recruiting	Photodynamic Diagnosis of Upper Tract Urothelial Carcinoma Using Fluorescence Endoscopy and Oral 5-ALA NCT06948552	Henry Ford Health System	Phase 2
Not Yet Recruiting	Multimodal Kidney-Sparing Strategy for High-Risk Upper Tract Urothelial Carcinoma NCT07504939	Peking University First Hospital	—
Recruiting	Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma NCT07492628	Beijing Biotech	Phase 1
Not Yet Recruiting	NECTAR Study: Neoadjuvant Toripalimab + 9MW2821 for Local UTUC NCT07412171	Peking University Third Hospital	Phase 2
Recruiting	Radical Nephroureterectomy With vs Without Template Lymph Node Dissection in High-Risk Upper Tract Urothelial NCT07321210	Tianjin Medical University Second Hospital	N/A
Recruiting	Cisplatin-Based Chemotherapy Followed by Maintenance Avelumab in UTUC NCT07225374	Samsung Medical Center	Phase 2
Recruiting	Neoadjuvant Tislelizumab in Combination With Nab-Paclitaxel for UTUC NCT07126119	Tianjin Medical University Second Hospital	Phase 2
Recruiting	Ambulatory Flexible URS for UTUC Surveillance NCT06848868	Chinese University of Hong Kong	Phase 1
Not Yet Recruiting	HEFTME System for Adjuvant Therapeutic Selection of Locally Advanced UTUC Postoperatively：A Perspective Cohort NCT06798246	Peking University First Hospital	—
Recruiting	A Home-Based Prehabilitation Exercise Intervention for Improving Physical Function in Patients With Bladder Ca NCT06040762	University of Washington	N/A
Recruiting	A Study of RC48-ADC Combined with JS001 for Postoperative Adjuvant Treatment of Upper Tract Urothelial Carcino NCT05917158	Jinling Hospital, China	Phase 2
Unknown	Diagnostic Evaluation of Urine DNA Methylation/Somatic Mutation Profiling for Upper Tract Urothelial Carcinoma NCT04948528	AnchorDx Medical Co., Ltd.	—
Completed	Treatment of Tumors in the Urinary Collecting System of the Kidney or Ureter Using a Light Activated Drug (WST NCT03617003	Memorial Sloan Kettering Cancer Center	Phase 1
Unknown	Feasibility of Neo-adjuvant Versus Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma NCT02969083	The European Uro-Oncology Group	Phase 2
Unknown	Feasibility and Safety of Extraperitoneal Laparoscopic Extended Retroperitoneal Lymph Node Dissection at Time NCT03544437	RenJi Hospital	—
Unknown	Lymph Node Dissection in High-risk UTUC(Upper Tract Urothelial Carcinoma) NCT03230201	Peking University First Hospital	N/A
Unknown	Prophylactic Intravesical Chemotherapy to Prevent Bladder Recurrence After Nephroureterectomy for Primary Uppe NCT02923557	Peking University First Hospital	Phase 2
Unknown	Prophylactic Intravesical Chemotherapy to Prevent Bladder Recurrence After Diagnostic Ureteroscopy for Primary NCT02740426	Peking University First Hospital	Phase 2
Unknown	Prophylactic Intravesical Chemotherapy to Prevent Bladder Tumors After Nephroureterectomy for Primary Upper Ur NCT02547350	Xuesong Li	Phase 2